Fredericus Eskens

953 total citations
3 papers, 13 citations indexed

About

Fredericus Eskens is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Fredericus Eskens has authored 3 papers receiving a total of 13 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 3 papers in Immunology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Fredericus Eskens's work include Cancer Immunotherapy and Biomarkers (3 papers), Immunotherapy and Immune Responses (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Fredericus Eskens is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Immunotherapy and Immune Responses (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Fredericus Eskens collaborates with scholars based in Netherlands, Japan and United States. Fredericus Eskens's co-authors include Adi Diab, Toshihiko Doi, Jean‐Philippe Spano, Siwen Hu‐Lieskovan, Omid Hamid, Alison Forgie, Jeffrey Chou, Wenjing Yang, Ray Li and Jacob Thomas and has published in prestigious journals such as Cancer Research, Annals of Oncology and Poster presentations.

In The Last Decade

Fredericus Eskens

2 papers receiving 12 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fredericus Eskens Netherlands	2	12	7	3	2	2	3	13
Lotte Hoeijmakers Netherlands	3	11 0.9×	6 0.9×	3 1.0×	2 1.0×	2 1.0×	6	25
Chuan Gu China	2	17 1.4×	12 1.7×	2 0.7×	2 1.0×	3 1.5×	4	27
Robyn Burns United States	2	10 0.8×	6 0.9×	4 1.3×	1 0.5×	1 0.5×	2	13
Jason M. Romero United States	2	15 1.3×	8 1.1×	2 0.7×		1 0.5×	4	16
S. Yang China	3	8 0.7×	4 0.6×	4 1.3×	4 2.0×	2 1.0×	5	16
Jae Eun Choi United States	2	16 1.3×	4 0.6×	5 1.7×		2 1.0×	3	17
Cristina Costan France	2	12 1.0×	3 0.4×	3 1.0×	2 1.0×		3	16
James Perera United Kingdom	1	6 0.5×	8 1.1×	2 0.7×	3 1.5×		2	18
Toby Talbot United Kingdom	3	18 1.5×	9 1.3×	3 1.0×	1 0.5×	5 2.5×	7	21
Chi-Wan Chow United States	3	9 0.8×	3 0.4×	4 1.3×	1 0.5×	2 1.0×	9	11

Countries citing papers authored by Fredericus Eskens

Since Specialization

Citations

This map shows the geographic impact of Fredericus Eskens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fredericus Eskens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fredericus Eskens more than expected).

Fields of papers citing papers by Fredericus Eskens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fredericus Eskens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fredericus Eskens. The network helps show where Fredericus Eskens may publish in the future.

Co-authorship network of co-authors of Fredericus Eskens

This figure shows the co-authorship network connecting the top 25 collaborators of Fredericus Eskens. A scholar is included among the top collaborators of Fredericus Eskens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fredericus Eskens. Fredericus Eskens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

3 of 3 papers shown

1.

Chiappori, Alberto, John A. Thompson, Fredericus Eskens, et al.. (2020). P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort. Poster presentations. A9–A10. 11 indexed citations

2.

Diab, Adi, Omid Hamid, John A. Thompson, et al.. (2018). Abstract CT010: Pharmacodynamic (PD) changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600). Cancer Research. 78(13_Supplement). CT010–CT010.

3.

Hamid, Omid, Willeke Ros, John A. Thompson, et al.. (2017). Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb. Annals of Oncology. 28. v406–v406. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact